Estudio farmacocinético poblacional de medicamentos de interés terapéutico evaluados en la práctica clínica

Abstract

Population pharmacokinetics lead the study of drug kinetics, thanks to the determination of pharmacokinetic parameters in a population and the analysis of the inter- or intrapersonal variation of the pharmacological response of each individual. The response of the drug can vary according to various factors related to the pathophysiological condition of each individual, for example: gender, age, race, pathologies, etc. The present investigation compiled pharmacokinetic studies of drugs of therapeutic interest for the evaluation of their behavior in patients in clinical practice. Of the drugs analyzed, it was found that, in phenytoin, the level of plasma concentrations is 4 - 8 mg / L, which indicates that it is at a lower value than previous studies, due to instability of the half-life. Likewise, in patients with septic shock, the kinetics of meropenem are altered due to the pathophysiology of the patients. Similarly, it was evidenced that the clearance variable, when administering cyclosporine, in patients with refractory nephrotic syndrome is high. Also, the volume of distribution data when administering hydroxychloroquine in COVID patients, this can be attributed to modulators of CYP2D6e. Furthermore, in a lamotrigine monitoring study it was shown that clearance is a pharmacokinetic variable that has pharmacokinetic interactions among its predictors. However, vancomycin pharmacokinetic parameters were similar to past studies.